Singapore, Aug. 18 -- Eisai Co. has announced that the in-house discovered and developed orexin receptor antagonist DAYVIGO(R) (brand name in China: "DAYVIGO(R)" generic name: lemborexant) has launched in China for the treatment of adults with insomnia, characterised by difficulties with sleep onset and/or sleep maintenance. Eisai received approval for DAYVIGO in China on May 27, 2025. This marks the first orexin receptor antagonist to be launched in China.

DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). Unlike conventional treatments such as benzodiazepines that act directly on sleepiness, DA...